Principal Financial Group
DAWN

Principal Financial Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Principal Financial Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,977
Closed -$297K – 2393
2024
Q1 		$297K Buy
17,977
+108
+0.6% +$1.62K ﹤0.01% 2089
2023
Q4 		$261K Buy
17,869
+88
+0.5% +$1.07K ﹤0.01% 2097
2023
Q3 		$218K Buy
17,781
+1,569
+10% +$20.5K ﹤0.01% 2140
2023
Q2 		$194K Buy
16,212
+2,499
+18% +$32.6K ﹤0.01% 2190
2023
Q1 		$183K Buy
13,713
+685
+5% +$13.4K ﹤0.01% 2197
2022
Q4 		$280K Buy
+13,028
New +$267K ﹤0.01% 2122

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Principal Financial Group's DAWN Position: Q2 2024 in Review

Principal Financial Group sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 17,977 shares — an estimated $297K sold.

Principal Financial Group first reported a position in DAWN in Q4 2022 and held it in 6 quarters. The position peaked at $297K in Q1 2024. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Principal Financial Group reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 17,977 Day One Biopharmaceuticals shares in Q2 2024, an estimated $297K.
  • Principal Financial Group first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Principal Financial Group's Day One Biopharmaceuticals position peaked at $297K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.